Table 4.
Summary of the main results for the most commonly analyzed variables related to BDNF and Bipolar Disorder. Studies that found a significant difference in treatment response are signaled with + in effect (last column); those that did not find a significant difference in treatment response are signaled with n.s. A meta-analisis was included here, marked with an asterisk (*).
| Author | Ref | Treatment | Sample | BDNF Non Responders | BDNF Responders | Effect |
|---|---|---|---|---|---|---|
| Masui T., et al., 2006 | [36] | Pharmacological (Lithium) | Val66Met | Val/Val 31.3% (n = 16), Val/Met 52.9% (n = 27), Met/Met 15.6% (n = 8) |
Val/Val 37.2% (n = 41), Val/Met 50% (n = 55), Met/Met 12.7% (n = 14) |
n.s. |
| Michelon L., et al., 2006 | [37] | Pharmacological (Lithium) | BDNF | TT 63.2% (n = 35) CT 34.7% (n = 17) CC 2.0% (n = 1) |
TT 66.1% (n = 39) CT 32.2% (n = 19) CC 1.7% (n = 1) |
n.s. |
| Suwalska A., et al., 2010 | [38] | Pharmacological (Lithium) | Plasma | 21.9 ± 15.5 ng/mL (n = 50) | 26.7 ± 16.8 ng/mL (n = 30) | + |
| Rybakowski JK., et al., 2011 | [39] | Pharmacological (Lithium) | Val66Met | Met/Val + Met/Met 24% Val/Val 76% |
Met/Val + Met/Met 56% Val/Val 44% |
+ |
| Ehret MJ., et al., 2013 * | [40] | Pharmacological (Lithium) | Val66Met | Val/Met | Val/Val | + |
| Rybakowski JK. 2014a | [41] | Pharmacological (Lithium) | Val66Met | Val/Val | Val/Met | + |
| Rybakowski JK. 2014b | [42] | Pharmacological (Lithium) | Val66Met | Val/Val | Val/Met | + |
| Reinares M., et al., 2020 | [43] | Non-pharmacological (Psycho-education) | Plasma | 21.14 ± 10.35 ng/mL (n = 43) | 27.37 ± 10.70 ng/mL (n = 47) | + |